Bristol Myers rises on positive trial results for cancer and lung disease drugs
BMY•Bristol Myers Squibb shares rose 3.7% premarket after the company reported positive results for its experimental lung disease drug admilparant and cancer therapy RYZ101.
1. Trial results
Bristol Myers Squibb said a 60-mg dose of admilparant taken twice daily met the main goal in a late-stage trial, showing a statistically significant benefit over placebo in preserving lung function in patients with idiopathic pulmonary fibrosis. Separately, RYZ101 significantly delayed disease progression in patients with rare, advanced gastrointestinal and pancreatic tumors that had progressed after earlier treatment.
